Please use this identifier to cite or link to this item: https://repository.southwesthealthcare.com.au/swhealthcarejspui/handle/1/3664
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCollins, Ian M.-
dc.contributor.authorKanjanapan, Yada-
dc.contributor.authorWen Lok, Sheau-
dc.contributor.authorGibbs, Peter-
dc.contributor.authorDe Boer, Richard-
dc.contributor.authorYeo, Belinda-
dc.contributor.authorGreenberg, Sally-
dc.contributor.authorBarnett, Frances-
dc.contributor.authorKnott, Louise-
dc.contributor.authorRichardson, Gary-
dc.contributor.authorWong, Rachel-
dc.contributor.authorNottage, Michelle-
dc.contributor.authorTorres, Javier-
dc.contributor.authorLombard, Janine-
dc.contributor.authorJohns, Julie-
dc.contributor.authorHarold, Michael-
dc.contributor.authorMalik, Laeeq-
dc.date.accessioned2023-04-05T06:20:19Z-
dc.date.available2023-04-05T06:20:19Z-
dc.date.issued2020-11-
dc.identifier.issn0167-6806en
dc.identifier.urihttps://repository.southwesthealthcare.com.au/swhealthcarejspui/handle/1/3664-
dc.description.abstractPurpose: Trastuzumab, pertuzumab, and docetaxel are the standard first-line therapy for HER2-positive (HER2+) metastatic breast cancer (MBC). However, only 10% of patients received neoadjuvant and/or adjuvant trastuzumab (NAT) in the registration trial (NCT00567190). In contemporary practice, the majority of recurrent HER2+ MBC patients had prior NAT. We explore any impact of prior therapy on the efficacy of dual HER2-targeted antibody with taxane therapy for metastatic disease. Methods: Utilising a prospective national registry, clinico-pathological, treatment, and outcome data for HER2+ MBC patients diagnosed between October 2006 and January 2019 were collected. Survival was estimated by the Kaplan-Meier method and compared among groups by log-rank test. Results: Of 287 HER2+ MBC patients, 222 (77%) received first-line trastuzumab, pertuzumab, and taxane therapy. There were 130 (45%) with de novo MBC. Of the recurrent MBC patients 107/157 (68%) had received NAT. The median progression-free survival (PFS) among patients who received NAT was 15.8 months compared with 24.3 months without prior NAT (hazard ratio [HR] 1.45, 95% CI 1.05-2.03, p = 0.03). The median overall survival (OS) was 42.7 months in patients who had NAT, and was not reached in those who did not (HR 1.80, 95% CI 1.12-2.90, p = 0.02). However, when excluding de novo MBC patients, prior NAT exposure was no longer significantly associated with survival (p = 0.11). De novo MBC patients had the longest median PFS (25.2 months) and OS (91.2 months). Conclusions: Prior receipt of NAT was associated with inferior median PFS following first-line HER2-based therapy in the metastatic setting. However, prior NAT exposure did not significantly impact OS, supporting the efficacy of taxane, trastuzumab, pertuzumab combination for first-line HER2+ MBC regardless of prior NAT exposure. Patients with de novo MBC had the longest survival, suggesting stratification for synchronous versus metachronous disease in prospective clinical trials of MBC should be considered. Keywords: De novo; Metastatic breast cancer; Pertuzumab; Trastuzumab.en
dc.publisherSpringeren
dc.titleImpact of prior (neo)adjuvant trastuzumab (NAT) exposure on the efficacy of HER2-targeted therapy for metastatic breast canceren
dc.typeJournal Articleen
dc.identifier.journaltitleBreast Cancer Research and Treatmenten
dc.identifier.urlhttps://doi.org/10.1007/s10549-020-05825en
dc.description.affiliation1The Canberra Hospital, Canberra, Australia. yada.kanjanapan@yahoo.com. 2Walter and Eliza Hall Institute, Melbourne, Australia. 3Peter MacCallum Cancer Centre, Melbourne, Australia. 4Olivia Newton John Cancer Centre, Melbourne, Australia. 5Western Health, Melbourne, Australia. 6Northern Health, Melbourne, Australia. 7Royal Hobart Hospital, Hobart, Australia. 8Cabrini Institute, Melbourne, Australia. 9Eastern Health, Melbourne, Australia. 10Royal Brisbane Hospital, Brisbane, Australia. 11South Western Oncology, Warrnambool, VIC, Australia. 12Goulburn Valley Health, Shepparton, VIC, Australia. 13Calvary Mater Newcastle, Newcastle, Australia. 14The Canberra Hospital, Canberra, Australia.en
dc.format.startpage87en
dc.source.volume184en
local.issue.number1en
dc.format.pages87-95en
dc.identifier.importdoi10.1007/s10549-020-05825en
dc.identifier.date2020-08-
dc.contributor.swhauthorCollins, Ian M.-
Appears in Collections:SWH Staff Publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Google Media

Google ScholarTM

Who's citing